Categories
Change Password!
Reset Password!
Lasmiditan
could be a treatment of choice for acute migraine patients with a
cardiovascular risk profile due to its considerable effectiveness, safety and quality
of lacking vasoconstriction.
A migraine is a
painful headache and triptans are available drugs for this acute attack
treatment. But because of its vasoconstrictive properties, these drugs are
prohibited in patients with vascular conditions. Other limitations of these
drugs include side effects like inconsistency in therapeutic action and
possible non-responsiveness.
Lasmiditan, a highly selective 5-HT1F receptor agonist, acts as a novel acute anti-migraine agent which does not cause vasoconstriction.
The recent article published in Expert Opin Pharmacother evaluated the clinical efficacy and safety of oral and intravenous Lasmiditan as treatment approach for migraine. This was a review that analysed all currently available results in Phase I to III studies.
The analysis of
studies showed a significant headache improvement in patients treated with
Lasmiditan than placebo. It also showed
that Lasmiditan is a promising acute migraine therapy, specifically in patients
at increased cardiovascular risk. The clinical efficacy of Lasmiditan proves
that vasoconstriction is not essential for acute migraine therapy but also
points to a well-established trigeminal contribution, to central neuronal
mechanisms in migraine pathophysiology. Lasmiditan penetrates the blood-brain
barrier, so CNS associated adverse events are common. But these side effects
are often mild to moderate severity. The results of long-term Phase III studies
will determine if these adverse events represent a limitation in clinical
practice.
Expert Opin Pharmacother. 2017 Jul 27
The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.
Raffaelli B et. al.
Comments (0)